Senti Biosciences Inc (SNTI)

$0.48

Market is closed - opens 7 PM, 28 Sep 2023

Insights on Senti Biosciences Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 2.77M → 937.0K (in $), with an average decrease of 40.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -41.57M → -18.69M (in $), with an average increase of 61.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 84.6% return, outperforming this stock by 150.3%

Performance

  • $0.48
    $0.52
    $0.48
    downward going graph

    0.0%

    Downside

    Day's Volatility :7.69%

    Upside

    7.69%

    downward going graph
  • $0.38
    $8.77
    $0.48
    downward going graph

    20.27%

    Downside

    52 Weeks Volatility :95.64%

    Upside

    94.53%

    downward going graph

Returns

PeriodSenti Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
-20.0%
-1.1%
0.0%
6 Months
-58.97%
1.6%
0.9%
1 Year
-65.71%
4.2%
3.1%
3 Years
-95.17%
24.2%
17.1%

Highlights

Market Capitalization
30.0M
Book Value
$2.19
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.3
Wall Street Target Price
4.0
Profit Margin
0.0%
Operating Margin TTM
-1892.02%
Return On Assets TTM
-27.66%
Return On Equity TTM
-57.43%
Revenue TTM
4.0M
Revenue Per Share TTM
0.09
Quarterly Revenue Growth YOY
-31.0%
Gross Profit TTM
-29.8M
EBITDA
-74.5M
Diluted Eps TTM
-0.3
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.53
EPS Estimate Next Year
-1.08
EPS Estimate Current Quarter
-0.48
EPS Estimate Next Quarter
-0.41

Analyst Recommendation

Buy
    70%Buy
    30%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Senti Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 733.33%

Current $0.48
Target $4.00

Company Financials

FY20Y/Y Change
Revenue
394.0K
-
Net Income
-19.9M
-
Net Profit Margin
-5.0K%
-
FY21Y/Y Change
Revenue
2.3M
↑ 481.47%
Net Income
-55.3M
↑ 178.52%
Net Profit Margin
-2.4K%
↑ 2626.5%
FY22Y/Y Change
Revenue
4.3M
↑ 87.08%
Net Income
-58.2M
↑ 5.23%
Net Profit Margin
-1.4K%
↑ 1056.48%
Q2 FY22Q/Q Change
Revenue
1.4M
-
Net Income
-11.6M
↑ 781.93%
Net Profit Margin
-850.66%
-
Q3 FY22Q/Q Change
Revenue
1.8M
↑ 30.04%
Net Income
-16.6M
↑ 44.04%
Net Profit Margin
-942.24%
↓ 91.58%
Q4 FY22Q/Q Change
Revenue
2.8M
↑ 56.85%
Net Income
-41.6M
↑ 149.82%
Net Profit Margin
-1.5K%
↓ 558.48%
Q1 FY23Q/Q Change
Revenue
1.3M
↓ 53.57%
Net Income
-18.7M
↓ 54.96%
Net Profit Margin
-1.5K%
↑ 44.89%
Q2 FY23Q/Q Change
Revenue
937.0K
↓ 27.14%
Net Income
-18.7M
↓ 0.13%
Net Profit Margin
-2.0K%
↓ 539.58%
FY20Y/Y Change
Total Assets
48.3M
-
Total Liabilities
107.1M
-
FY21Y/Y Change
Total Assets
96.7M
↑ 100.02%
Total Liabilities
208.2M
↑ 94.44%
FY22Y/Y Change
Total Assets
180.8M
↑ 86.96%
Total Liabilities
53.5M
↓ 74.28%
Q1 FY22Q/Q Change
Total Assets
230.9M
↓ 0.23%
Total Liabilities
11.1M
↑ 7.44%
Q2 FY22Q/Q Change
Total Assets
202.4M
↓ 12.37%
Total Liabilities
48.1M
↑ 333.25%
Q3 FY22Q/Q Change
Total Assets
189.4M
↓ 6.39%
Total Liabilities
49.1M
↑ 2.08%
Q4 FY22Q/Q Change
Total Assets
180.8M
↓ 4.57%
Total Liabilities
53.5M
↑ 9.02%
Q1 FY23Q/Q Change
Total Assets
161.4M
↓ 10.71%
Total Liabilities
49.1M
↓ 8.3%
Q2 FY23Q/Q Change
Total Assets
143.6M
↓ 11.02%
Total Liabilities
46.2M
↓ 5.85%
FY19Y/Y Change
Operating Cash Flow
-18.4M
-
Investing Cash Flow
3.8M
-
Financing Cash Flow
14.0M
-
FY20Y/Y Change
Operating Cash Flow
-24.2M
↑ 31.53%
Investing Cash Flow
11.4M
↑ 202.8%
Financing Cash Flow
38.1M
↑ 171.56%
FY21Y/Y Change
Operating Cash Flow
-34.6M
↑ 43.28%
Investing Cash Flow
-5.5M
↓ 148.8%
Financing Cash Flow
68.4M
↑ 79.85%
Q1 FY22Q/Q Change
Operating Cash Flow
-492.6K
↓ 158.68%
Investing Cash Flow
-7.4M
↑ 85.19%
Financing Cash Flow
-455.0K
↓ 2078.26%
Q2 FY22Q/Q Change
Operating Cash Flow
-15.3M
↑ 2997.94%
Investing Cash Flow
-18.6M
↑ 152.57%
Financing Cash Flow
118.2M
↓ 26069.23%
Q3 FY22Q/Q Change
Operating Cash Flow
-10.1M
↓ 33.58%
Investing Cash Flow
-14.2M
↓ 23.81%
Financing Cash Flow
-485.0K
↓ 100.41%
Q4 FY22Q/Q Change
Operating Cash Flow
-24.8M
↑ 144.28%
Investing Cash Flow
-49.1M
↑ 245.88%
Financing Cash Flow
119.0M
↓ 24643.51%
Q1 FY23Q/Q Change
Operating Cash Flow
-16.3M
↓ 34.15%
Investing Cash Flow
-9.5M
↓ 80.66%
Financing Cash Flow
-35.0K
↓ 100.03%
Q2 FY23Q/Q Change
Operating Cash Flow
-13.7M
↓ 16.12%
Investing Cash Flow
18.3M
↓ 293.02%
Financing Cash Flow
281.0K
↓ 902.86%

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Senti Biosciences Inc
Senti Biosciences Inc
-22.95%
-58.97%
-65.71%
-95.17%
-95.17%
Moderna, Inc.
Moderna, Inc.
-12.64%
-32.32%
-18.59%
40.95%
434.62%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.2%
0.68%
18.02%
45.57%
106.06%
Novo Nordisk A/s
Novo Nordisk A/s
-2.18%
18.08%
84.58%
165.14%
289.05%
Seagen, Inc.
Seagen, Inc.
3.05%
4.69%
54.33%
11.57%
175.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.55%
11.62%
19.58%
30.6%
81.41%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Senti Biosciences Inc
Senti Biosciences Inc
NA
NA
NA
-1.53
-0.57
-0.28
0.0
2.19
Moderna, Inc.
Moderna, Inc.
34.67
34.67
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.73
21.73
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.3
43.3
2.03
1.65
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.94
26.94
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Senti Biosciences Inc
Senti Biosciences Inc
Buy
$30.0M
-95.17%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$37.3B
434.62%
34.67
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.4B
106.06%
21.73
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$410.6B
289.05%
43.3
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$40.6B
175.61%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.2B
81.41%
26.94
35.4%

Institutional Holdings

  • NEA Management Company, LLC

    9.94%

  • T. Rowe Price Associates, Inc.

    7.62%

  • ARK Investment Management LLC

    4.11%

  • Intel Corp

    1.34%

  • Vanguard Group Inc

    1.24%

  • Hongkou Capital LP

    0.67%

Company Information

senti biosciences is a team of engineers, scientists, and entrepreneurs on a mission to leverage synthetic biology to treat the most pressing diseases. they have pioneered new technology platforms to design synthetic gene circuits for adaptive cell and gene therapies. their recently completed series a round of funding will be used to further the growth of their scalable therapeutic design platform and advance therapeutic candidates towards the clinic. they are proud to count nea, 8vc, amgen ventures, pear ventures, lux capital, menlo ventures, allen & company, nest.bio, omega funds, goodman capital, and lifeforce capital among their investors.

Organization
Senti Biosciences Inc
Employees
122
CEO
Dr. Timothy K. Lu M.D., Ph.D.
Industry
Healthcare

Discover More

FAQs